Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates (Q36217148)

12 August 2017

1 reference

title

Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates (English)

1 reference

12 August 2017

1 reference

Jonathan R Green

1

1 reference

PubMed ID

16076701

12 August 2017

language of work or name

1 reference

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

44

1 reference

12 August 2017

3

1 reference

12 August 2017

282-292

1 reference

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

12 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F02841860510029644

Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510029644

Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510029644

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510029644

Markers of bone turnover for the management of patients with bone metastases from prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510029644

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510029644

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510029644

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510029644

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510029644

A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510029644

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510029644

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510029644

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510029644

In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510029644

Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510029644

The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510029644

A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510029644

Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510029644

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510029644

Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510029644

Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510029644

10.1080/02841860510029644

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

16076701